Research programme: Escherichia coli vaccine - Baxter International/Roche

Drug Profile

Research programme: Escherichia coli vaccine - Baxter International/Roche

Latest Information Update: 01 Apr 2011

Price : $50

At a glance

  • Originator Baxter International
  • Developer Baxter International; Roche
  • Class Escherichia coli vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Urinary tract infections

Most Recent Events

  • 26 Jun 2007 BioVeris Corporation has been acquired and merged into Roche
  • 12 Oct 2000 New profile
  • 12 Oct 2000 Preclinical development for Urinary tract infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top